A small droplet that contains the coronavirus can infect someone with SARS-CoV-2, according to recent results from the first COVID-19 human challenge study.
Sutimlimab-jome is the first drug to have FDA approval for the treatment cold agglutinin disease, a rare autoimmune hemolytic anemia in which antibodies destroy red blood cells.